换一批
换一批Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.
第一作者：
Ferry A L M,Eskens
第一单位：
Authors' Affiliations: Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain; Eisai Inc., Woodcliff Lake, New Jersey; Eisai Inc., Tsukuba, Japan; and Memorial Sloan-Kettering Cancer Center, New York, New York.
作者：
主题词
老年人(Aged);抗生素类, 抗肿瘤(Antibiotics, Antineoplastic);细胞凋亡(Apoptosis);用药计划表(Drug Administration Schedule);环氧化合物(Epoxy Compounds);女(雌)性(Female);人类(Humans);白细胞, 单核(Leukocytes, Mononuclear);大环内酯类(Macrolides);男(雄)性(Male);最大耐受剂量(Maximum Tolerated Dose);中年人(Middle Aged);肿瘤(Neoplasms);RNA, 信使(RNA, Messenger);剪接体(Spliceosomes);治疗结果(Treatment Outcome)
DOI
10.1158/1078-0432.CCR-13-0485
PMID
23983259
发布时间
2022-04-08
- 浏览298
Clinical cancer research
6296-304页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
